Literature DB >> 17512521

Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.

Shinji Takai1, Daisuke Yamamoto, Denan Jin, Sachiko Inagaki, Katsuhiro Yoshikawa, Kazuhiko Tanaka, Mizuo Miyazaki.   

Abstract

We measured angiotensin-converting enzyme and matrix metalloproteinase-9 activities after myocardial infarction in hamsters and compared the effects of an angiotensin-converting enzyme inhibitor lisinopril with those of an angiotensin receptor blocker candesartan cilexetil after myocardial infarction. Angiotensin-converting enzyme activity was significantly increased 3 and 7 days, but not 1 day after myocardial infarction. Matrix metalloproteinase-9 activity was significantly increased 1 day after myocardial infarction. Lisinopril significantly inhibited both angiotensin-converting enzyme and matrix metalloproteinase-9 activities, but candesartan cilexetil did not. Angiotensin-converting enzyme inhibitors might directly inhibit matrix metalloproteinase-9 activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512521     DOI: 10.1016/j.ejphar.2007.04.036

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling.

Authors:  Merry L Lindsey
Journal:  Nat Rev Cardiol       Date:  2018-08       Impact factor: 32.419

2.  Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension.

Authors:  Rikki M Tanner; Amy I Lynch; Victoria H Brophy; John H Eckfeldt; Barry R Davis; Charles E Ford; Eric Boerwinkle; Donna K Arnett
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

3.  Development of drug delivery systems based on layered hydroxides for nanomedicine.

Authors:  Farahnaz Barahuie; Mohd Zobir Hussein; Sharida Fakurazi; Zulkarnain Zainal
Journal:  Int J Mol Sci       Date:  2014-05-05       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.